We confirmed increased LATS2 expression and sustained Hippo pathway activation (pYAP) in Merlin-deficient schwannoma after MLN3651 treatment for 72 h, suggesting that MLN3651 inhibits CRL4-DCAF1 activity in Merlin-deficient cells (Figure S3A). The gene discussed is DCAF1; the disease is schwannoma.